New Study on Dulaglutide and Diabetic Foot Complications Published

A new study involving dulaglutide was published on September 11, 2026, in The International Journal of Lower Extremity Wounds. The publication is titled "Assessing the Association Between GLP-1 Receptor Agonists and Diabetic Foot Complications Using Real-World Pharmacovigilance Database and Mendelian Randomization." Dulaglutide is an approved compound in the GLP-1 receptor agonist class referenced in the study title. The publication indicates that researchers used a real-world pharmacovigilance database along with Mendelian randomization methods as part of the analysis. No specific findings, results, or conclusions from the study have been provided beyond the title and publication details. This entry reflects only the fact that the publication exists, its title, its journal, and its publication date. Readers interested in the broader background of dulaglutide, including its regulatory status and general information, can consult the compound overview for additional context.